P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib

Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits EGFR TKI-sensitizing and EGFR T790M resistance mutations with demonstrated efficacy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC), including central nervous system (CNS) metastases. Osimertinib is the preferred first-line treatment in EGFRm advanced NSCLC; however, progression eventually occurs. Guidelines recommend that upon systemic progression, osimertinib be discontinued and platinum-based doublet chemotherapy be initiated.